Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 27 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 472.78, with a low estimate of 351 and a high estimate of 583. The average target predicts an increase of 47.51% from the current stock price of 320.51.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$351	$472.78	$473	$583
Change	+9.51%	+47.51%	+47.58%	+81.90%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock from 28 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	14	13	13	13	12	13
Buy	11	11	10	10	10	10
Hold	4	3	4	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	29	27	27	28	27	28

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick R. Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $510	Strong Buy	Reiterates	$510	+59.12%	Feb 18, 2026
Ilya Zubkov Freedom Capital Markets	Freedom Capital Markets	Hold → Strong Buy Upgrades $470 → $410	Hold → Strong Buy	Upgrades	$470 → $410	+27.92%	Feb 17, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $415 → $429	Strong Buy	Maintains	$415 → $429	+33.85%	Feb 17, 2026
Keay Nakae Chardan Capital	Chardan Capital	Strong Buy Maintains $475 → $425	Strong Buy	Maintains	$475 → $425	+32.60%	Feb 13, 2026
Joseph Stringer Needham	Needham	Strong Buy Maintains $529 → $510	Strong Buy	Maintains	$529 → $510	+59.12%	Feb 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.67B

from 3.71B

52.78%

from 3.71B

Revenue Next Year

7.48B

from 5.67B

31.86%

from 5.67B

EPS This Year

7.46

from 2.33

220.23%

from 2.33

EPS Next Year

11.16

from 7.46

49.58%

from 7.46

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	844.29M	1.04B	1.83B	2.25B	3.71B	5.67B	7.48B
Revenue Growth	71.31%	22.88%	76.24%	22.97%	65.19%	52.78%	31.86%
EPS	-7.20	-9.30	-3.52	-2.18	2.33	7.46	11.16
EPS Growth	-	-	-	-	-	220.23%	49.58%
Forward PE	-	-	-	-	-	42.96	28.72
No. Analysts	-	-	-	-	-	31	28

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	6.2B	8.6B
Avg	5.7B	7.5B
Low	5.1B	6.5B

Revenue Growth

Revenue Growth	2026	2027
High	67.3%	51.3%
Avg	52.8%	31.9%
Low	37.4%	15.3%

EPS Forecast

EPS	2026	2027
High	10.77	15.74
Avg	7.46	11.16
Low	4.79	7.60

EPS Growth

EPS Growth	2026	2027
High	362.4%	110.9%
Avg	220.2%	49.6%
Low	105.7%	1.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.